彭博利珠单抗辅助治疗肾细胞癌的总生存率--雷电的震撼

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-05-17 DOI:10.1038/s41585-024-00896-6

Francesco Massari, Matteo Rosellini, Veronica Mollica

{"title":"彭博利珠单抗辅助治疗肾细胞癌的总生存率--雷电的震撼","authors":"Francesco Massari, Matteo Rosellini, Veronica Mollica","doi":"10.1038/s41585-024-00896-6","DOIUrl":null,"url":null,"abstract":"In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"21 10","pages":"578-579"},"PeriodicalIF":12.1000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning\",\"authors\":\"Francesco Massari, Matteo Rosellini, Veronica Mollica\",\"doi\":\"10.1038/s41585-024-00896-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.\",\"PeriodicalId\":19088,\"journal\":{\"name\":\"Nature Reviews Urology\",\"volume\":\"21 10\",\"pages\":\"578-579\"},\"PeriodicalIF\":12.1000,\"publicationDate\":\"2024-05-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41585-024-00896-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41585-024-00896-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在KEYNOTE-564试验中，切除的透明细胞肾细胞癌患者复发风险较高，在接受pembrolizumab治疗后，无病生存期，尤其是总生存期获益匪浅，而pembrolizumab也被确定为这些患者的新型标准辅助疗法。准确选择患者至关重要。由于根据临床特征指导治疗决策的证据有限，处理 pembrolizumab 治疗后的复发具有挑战性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning

查看原文本刊更多论文

Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning

In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.